Evidence map›Paper›PMID 42614314›Full record

ReviewFrontiers in aging neuroscience2026

Emerging neuroprotective mechanisms and therapeutic potential of natural polysaccharides in Alzheimer's disease.

Noor Muhammad, Rui Ai, Limin Yang, Yuelong Cui, Liqiang Wang, Shaoting Weng, Yao Wang, Mohib Ullah Kakar, Suliman Khan, Sajjad Ahmad and 1 more

Abstract readReview
In one paragraph

Review in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Noor Muhammad *College of Biology and Food Engineering, Anyang Institute of Technology, Anyang, China.
Rui Ai *College of Biology and Food Engineering, Anyang Institute of Technology, Anyang, China.
Limin YangBiomedical Sciences, Radiation Therapy Department, Anyang District Hospital, Puyang, China.
Yuelong CuiBiomedical Sciences, Radiation Therapy Department, Anyang District Hospital, Puyang, China.
Liqiang WangBiomedical Sciences, Radiation Therapy Department, Anyang District Hospital, Puyang, China.
Shaoting WengCollege of Biology and Food Engineering, Anyang Institute of Technology, Anyang, China.
Yao WangCollege of Biology and Food Engineering, Anyang Institute of Technology, Anyang, China.
Mohib Ullah KakarFaculty of Marine Sciences, Lasbela University of Agriculture Water and Marine Sciences (LUAWMS), Uthal, Balochistan, Pakistan.
Suliman KhanFaculty of Veterinary and Animal Sciences, Lasbela University of Agriculture, Water and Marine Science, Uthal, Baluchistan, Pakistan.
Sajjad AhmadFaculty of Veterinary and Animal Sciences, Lasbela University of Agriculture, Water and Marine Science, Uthal, Baluchistan, Pakistan.
Imran IqbalDepartment of Pathology, NYU Grossman School of Medicine, New York University Langone Health, New York, NY, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and memory loss, affecting millions worldwide. Despite extensive research, effective treatments remain limited. Polysaccharides, abundant biological macromolecules derived from natural resources have emerged as promising therapeutic candidates due to their antioxidant, anti-inflammatory, and neuroprotective properties. This narrative review summarizes recent preclinical and limited clinical evidence on natural polysaccharides and their structure-activity relationships (SAR) in AD. We focus on their ability to mitigate amyloid-beta (Aβ) aggregation, reduce tau hyperphosphorylation, modulate neuroinflammation, and enhance cognitive function. We emphasize novel mechanistic insights and highlight how fungal, algal, plant, and bacterial polysaccharides exert broad multi-targeted effects. Importantly, this is the first review to integrate SAR with challenges of bioavailability and blood-brain barrier (BBB) penetration, offering a framework for optimizing therapeutic design. Novel insights into the molecular mechanisms, such as activation of Nrf2 and autophagy pathways, are discussed. We also underscore the translational value of polysaccharides, noting that strategies such as structural modification, nanoparticle conjugation, and pharmacokinetic profiling could accelerate their progression toward clinical application. However, most evidence is limited to

Indexed as

Alzheimer's disease (AD)neuroinflammationneuroprotectionpolysaccharidestau protein

Identifiers

PMID42614314
PMCPMC13481445

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.